JonesResearch analyst Soumit Roy downgraded Day One Biopharmaceuticals (DAWN) to Hold from Buy with a price target of $21.50, up from $20, after the company announced it will be acquired by Servier for $21.50 per share in cash, or $2.5B. The firm does not see any antitrust issues, saying Ojemda is still the first and only approved drug in its class. It views the sale price as inline with expectations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN: